Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Oct;187(10):651-5.
doi: 10.1007/s00066-011-2246-2. Epub 2011 Sep 23.

Accelerated radiotherapy with concomitant boost technique (69.5 Gy/5 weeks) : an alternative in the treatment of locally advanced head and neck cancer

Affiliations

Accelerated radiotherapy with concomitant boost technique (69.5 Gy/5 weeks) : an alternative in the treatment of locally advanced head and neck cancer

Jiri Kubes et al. Strahlenther Onkol. 2011 Oct.

Abstract

Background and purpose: To present the feasibility and results of accelerated radiotherapy with concomitant boost technique (69.5 Gy/5 weeks) in the treatment of locally advanced head and neck cancer.

Patients and methods: A total of 65 patients were treated between June 2006 and August 2009. The distribution of clinical stages was as follows: II 11%, III 23%, IV 61%, and not defined 5%.

Results: The median follow-up was 30.5 months. The treatment plan was completed in 94% of patients. Patients were treated using the conformal or intensity-modulated radiotherapy (IMRT) technique. The median overall treatment time was 37 days (13-45 days). The mean radiotherapy dose was 68.4 Gy (16-74 Gy). Overall survival was 69% after 2 years. Disease-free survival was 62% after 2 years. Acute toxicity ≥ grade 3(RTOG scale) included mucositis (grade 3: 42.6%), pharynx (grade 3: 42.3%), skin (grade 3: 9.5%), larynx (grade 3: 4%), while late toxicity affected skin (grade 3: 6.25%) and salivary glands (grade 3: 3.7%).

Conclusion: Accelerated radiotherapy with concomitant boost technique is feasible in patients with locally advanced head and neck cancer, has an acceptable toxicity profile, and yields promising treatment results.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Strahlenther Onkol. 2010 Sep;186(9):511-6 - PubMed
    1. Clin Oncol (R Coll Radiol). 2008 Mar;20(2):113-26 - PubMed
    1. Radiother Oncol. 1994 Apr;31(1):14-22 - PubMed
    1. Lancet. 2003 Sep 20;362(9388):933-40 - PubMed
    1. Br J Radiol. 1994 Aug;67(800):790-4 - PubMed

MeSH terms

LinkOut - more resources